Hims & Hers Health (HIMS) to Release Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is projected to announce its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect Hims & Hers Health to post earnings of $0.09 per share and revenue of $578.9920 million for the quarter. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Monday, November 3, 2025 at 5:00 PM ET.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. During the same quarter in the prior year, the firm earned $0.06 EPS. The firm’s revenue was up 72.6% compared to the same quarter last year. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Hims & Hers Health Trading Up 3.4%

Shares of NYSE:HIMS opened at $45.55 on Friday. Hims & Hers Health has a 52 week low of $18.33 and a 52 week high of $72.98. The company’s 50 day moving average is $51.39 and its two-hundred day moving average is $50.29. The company has a market cap of $10.30 billion, a PE ratio of 56.94, a P/E/G ratio of 3.05 and a beta of 2.25. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. KeyCorp assumed coverage on Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Truist Financial lowered their price target on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Hims & Hers Health in a report on Tuesday, October 14th. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $38.92.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 13,749 shares of the stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $694,324.50. Following the completion of the sale, the insider owned 297,139 shares in the company, valued at $15,005,519.50. This represents a 4.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 145,000 shares of the company’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the completion of the sale, the chief financial officer directly owned 128,984 shares of the company’s stock, valued at $7,139,264.40. The trade was a 52.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 1,432,271 shares of company stock valued at $74,229,585. 13.71% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the first quarter worth $30,000. EverSource Wealth Advisors LLC lifted its stake in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares during the period. Palisade Capital Management LP purchased a new stake in shares of Hims & Hers Health in the second quarter valued at about $224,000. SkyView Investment Advisors LLC acquired a new position in shares of Hims & Hers Health during the second quarter worth about $226,000. Finally, Meiji Yasuda Asset Management Co Ltd. purchased a new position in Hims & Hers Health during the second quarter worth about $234,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.